Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Among authors: aftimos p. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.
Aftimos PG, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F. Aftimos PG, et al. Int J Oncol. 2013 Sep;43(3):919-26. doi: 10.3892/ijo.2013.2008. Epub 2013 Jul 8. Int J Oncol. 2013. Retraction in: Int J Oncol. 2025 Jan;66(1):1. doi: 10.3892/ijo.2024.5707 PMID: 23835698 Retracted.
Anticancer drug development: moving away from the old habits.
Ades F, Zardavas D, Aftimos P, Awada A. Ades F, et al. Among authors: aftimos p. Curr Opin Oncol. 2014 May;26(3):334-9. doi: 10.1097/CCO.0000000000000076. Curr Opin Oncol. 2014. PMID: 24614094 No abstract available.
Impact of tumor sequencing on the use of anticancer drugs.
Thomas F, Desmedt C, Aftimos P, Awada A. Thomas F, et al. Among authors: aftimos p. Curr Opin Oncol. 2014 May;26(3):347-56. doi: 10.1097/CCO.0000000000000078. Curr Opin Oncol. 2014. PMID: 24709974 Review.
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.
Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, Hendlisz A. Deleporte A, et al. Among authors: aftimos p. BMC Cancer. 2014 May 30;14:385. doi: 10.1186/1471-2407-14-385. BMC Cancer. 2014. PMID: 24885112 Free PMC article. Clinical Trial.
102 results